1. Evolocumab as treatment in lorlatinib-related hyperlipidemia.
- Author
-
Pérez Alonso L, Cervera Calero R, Campos Fernández de Sevilla MÁ, Moreno Palanco MÁ, and Gómez Cerezo JF
- Subjects
- Humans, Anaplastic Lymphoma Kinase, Lactams, Macrocyclic adverse effects, Protein Kinase Inhibitors adverse effects, Carcinoma, Non-Small-Cell Lung chemically induced, Lung Neoplasms chemically induced, Hyperlipidemias chemically induced, Hyperlipidemias drug therapy
- Abstract
Anti-PCSK9 monoclonal antibodies have reduced the risk of cardiovascular events in patients with atheroesclerosis cardiovascular disease. However, its use has not been described in hyperlipidemia associated with lorlatinib, a third-generation ALK tyrosin kinasa inhibitor approved as treatment for ALK-positive non-small cell lung cancer., (Copyright © 2023 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF